PDGFRA gain in low-grade diffuse gliomas

Journal of Neuropathology and Experimental Neurology

Volumn 72, Issue 1, 2013, Pages 61-66

  Motomura, Kazuya ^a   Mittelbronn, Michel ^b   Paulus, Werner ^c   Brokinkel, Benjamin ^d   Keyvani, Kathy ^e   Sure, Ulrich ^e   Wrede, Karsten ^e   Nakazato, Yoichi ^f   Tanaka, Yuko ^f   Nonoguchi, Naosuke ^a   Pierscianek, Daniela ^a,e   Kim, Young Ho ^a   Mariani, Luigi ^g,h   Vital, Anne ⁱ   Perry, Arie ^j   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Institute of Neuropathology   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f GUNMA UNIVERSITY   (Japan)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ CNRS   (France)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Diffuse astrocytoma; IDH1 2 mutations; MET gain; PDGFRA gain

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; ASTROCYTOMA; CELL POPULATION; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC SCREENING; GLIOMA; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; LABORATORY TEST; MAJOR CLINICAL STUDY; MET GENE; OLIGODENDROGLIOMA; PDGFRA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR GENE; SURVIVAL; TP53 GENE; TUMOR CELL;

BRAIN NEOPLASMS; FEMALE; HUMANS; MALE; MUTATION; OLIGODENDROGLIOMA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SURVIVAL RATE;

EID: 84871988946     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31827c4b5b     Document Type: Article

References (33)

1. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89
2. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-99
3. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-53
4. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009;15:6002-7
5. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73
6. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12
7. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73
8. Li A, Walling J, Ahn S, et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 2009;69:2091-99
9. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17: 98-110
10. Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010;177:2708-14
11. Cooper LA, Gutman DA, Long Q, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. Plos one 2010;5:e12548
12. Gorovets D, Kannan K, Shen R, et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 2012;18:2490-2501
13. Martinho O, Longatto-Filho A, Lambros MB, et al. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer 2009;101: 973-982
14. Pierscianek D, Kim YH, Motomura K, et al. MET Gain in diffuse astrocytomas is associated with poorer outcome. Brain Pathol Jun 1, 2012. doi: 10.1111/j.1750-3639.2012.00609.x. [Epub ahead of print]
15. Motomura K, Mittelbronn M, Paulus W, et al. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome. J Neuropathol Exp Neurol 2012;71:702-7
16. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011;20: 810-817
17. Szerlip NJ, Pedraza A, Chakravarty D, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A 2012;109:3041-46
18. Nobusawa S, Stawski R, Kim YH, et al. Amplification of the PDGFRA, KIT and KDR genes in glioblastomas: A population-based study. Neuropathology 2011;31:583-88
19. Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998;62:768-75
20. Nigro JM, Takahashi MA, Ginzinger DG, et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 2001;158:1253-62
21. Horbinski C, Miller CR, Perry A. Gone FISHing: Clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol 2011;21:57-73
22. Kim YH, Nonoguchi N, Paulus W, et al. Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss. Brain Pathol 2012;22:834-40
23. Kim YH, Lachuer J, Mittelbronn M, et al. Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations. Brain Pathol 2011;21:645-51
24. Heldin CH, Westermark B. Platelet-derived growth factor: Mechanism of action and possible in vivo function. Cell Regul 1990;1:555-66
25. Smith TC. Toleration and bioavailability of gemfibrozil in healthy men. Proc R Soc Med 1976;69(SUPPL2):24-27
26. Reigstad LJ, Varhaug JE, Lillehaug Jr. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 2005;272:5723-41
27. Goritz C, Dias DO, Tomilin N, et al. A pericyte origin of spinal cord scar tissue. Science 2011;333:238-42
28. McDermott U, Ames RY, Iafrate AJ, et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-Alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res 2009;69: 3937-3946
29. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 2010;28:1337-44
30. Blom T, Roselli A, Häyry V, et al. Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors. J Neurooncol 2010;97:217-24
31. Varela M, Ranuncolo SM, Morand A, et al. EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas. J Surg Oncol 2004;86:34-40
32. Ribom D, Andrae J, Frielingsdorf M, et al. Prognostic value of platelet derived growth factor alpha-receptor expression in grade 2 astrocytomas and oligoastrocytomas. J Neurol Neurosurg Psychiatry 2002;72:782-87
33. Paugh BS, Broniscer A, Qu C, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 2011;29: 3999-4006